news
RNAi drug Kylo-11 cuts heart disease risk by lowering Lp(a) 25%
New research in The Lancet shows Kylo-11, an RNA interference therapeutic, reduced lipoprotein(a) (Lp(a)) concentrations by 20-25%. This modest drop significantly cuts the risk of atherosclerotic cardiovascular disease and calcific aortic valve stenosis. It points to a new way to target a long-neglected heart risk factor.
New research in The Lancet shows Kylo-11, an RNA interference therapeutic, reduced lipoprotein(a) (Lp(a)) concentrations by 20-25%. This modest drop significantly cuts the risk of atherosclerotic cardiovascular disease and calcific aortic valve stenosis. It points to a new way to target a long-neglected heart risk factor.
The architecture take
The old story used to be that you couldn't really do anything about high Lp(a) levels. It's a genetic lottery, they said. But this Kylo-11 data, published in The Lancet, changes that. Getting a 20-25% drop in Lp(a) means a much bigger win for your cardiovascular system, lowering your risk of heart attacks and valve issues. I pay attention when a new mechanism shows it can shift a risk factor previously thought immutable. It’s not about just patching symptoms; it’s about going upstream to a genetic marker. This is where personalized medicine actually starts making sense, moving beyond broad dietary advice to targeting specific biochemical loads. Watch for more drugs in this class. They’re coming, and they'll redefine how we manage heart health.